



Abstract—Biomolecular pathways are building blocks of 
cellular biochemical function. Computational biology is in rapid 
transition from diagrammatic representation of pathways to 
quantitative and predictive mathematical models, which span 
time-scales, knowledge domains and spatial-scales.  This 
transition is being accelerated by high-throughput 
experimentation which isolates reactions and their corresponding 
rate constants. A grand challenge of systems biology is to model 
the whole cell by integrating these emerging quantitative models. 
Current integration approaches do not scale.  A new parallel 
computational architecture, CytoSolve, directly addresses this 
scalability issue.  Results are presented in the solution of a 
concrete biological model: the Epidermal Growth Factor 
Receptor (EGFR) pathway model published by Kholodenko. The 
EGFR pathway is selected since known solutions exist for this 
problem thus enabling direct comparison of the CytoSolve 
approach.   Results from this effort demonstrate that CytoSolve 
provides a core platform for addressing a grand challenge of 
Systems Biology to model the whole cell by integrating multiple 
biomolecular pathway models. 
 
Index Terms—systems biology, computational models, 
signaling networks.  
 
I. INTRODUCTION 
IOMOLECULAR pathways are building blocks of cellular 
biochemical function.  Computational biology is in rapid 
transition from diagrammatic representation of pathways 
to quantitative and predictive mathematical models, which 
span time-scales, knowledge domains and spatial-scales.  This 
transition is being accelerated by high-throughput 
experimentation which isolates reactions and their 
corresponding rate constants. A grand challenge of systems 
biology is to model the whole cell by integrating multiple 
biomolecular pathways. Current integration approaches do not 
scale.  A new parallel computational architecture, CytoSolve, 
based on earlier work on integrating multiple molecular 
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pathways by Ayyadurai et al (1), directly addresses this 
scalability issue.   
     Results from CytoSolve are presented in the solution of a 
concrete biological model: the Epidermal Growth Factor 
Receptor (EGFR) pathway model published by Kholodenko et 
al (2).   The EGFR pathway is selected since known solutions 
exist for this problem thus enabling direct comparison of the 
CytoSolve approach.  Snoep et al (3) have instantiated the 
Kholodenko EGFR model into a software language known as 
Systems Biology Markup Language (SBML), which can be 
computed on software programs including Cell Designer 
designed by Kitano (4) which, like other solvers, takes a 
monolithic approach towards modeling and solving 
biomolecular pathway models.  
By monolithic approach, it is meant the construction of a 
biomolecular pathway must be done exclusively within the 
framework of that one system.  Thus, if one considers all the 
pathways representing all biochemical functions of the whole 
cell, modeling of the whole cell, in a monolithic approach, will 
require all individual pathways to be loaded and integrated 
within this one system.  If individual pathways were developed 
in other computing systems, monolithic systems either do not 
support such integration or make such integration extremely 
onerous, at best. 
  The EGFR model was first constructed using Cell Designer’s 
monolithic approach to solve for the various species 
concentration levels, as predicted by Kholodenko.  CytoSolve 
was then used to solve the same EGFR problem but in a 
distributed fashion to yield near exact results as that of Cell 
Designer. These results demonstrate the viability of 
CytoSolve’s unique distributed approach not only to solve 
problems that monolithic approaches are capable of solving 
but also demonstrates CytoSolve’s flexibility and scalability in 
integrating multiple biomolecular pathway models, which 
monolithic approaches are incapable of doing.  In CytoSolve, 
any one pathway can exist in any format and there is no need 
to manually load, understand and interconnect each individual 
pathway, as is required in monolithic systems.  The CytoSolve 
approach, therefore, provides a core platform for addressing 
one of Systems Biology’s grand challenges: modeling the 
whole cell by integrating multiple biomolecular pathway 
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approach of CytoSolve to integrate and compute multiple 
biomolecular pathway models and contrast this approach to 
extant monolithic approaches.  To perform this evaluation, two 
elements are required:  
I. A concrete biomolecular pathway for which there exists 
both diagrammatic and mathematical representations along 
with known solutions; and, 
II. A proven monolithic approach for integrating and 
solving multiple biomolecular pathway models. 
Relative to (I), the EGFR pathway model of Kholodenko et 
al (1), as shown in Fig. 1 is selected.  Fig. 1 represents the 
whole EGFR model.   
Relative to (II), Cell Designer by Kitano et al (4) is selected 
as the monolithic method. There are many other systems such 
as Cell Designer that could have been selected; this tool was 
selected primarily based on its current popular use in the 
systems biology community. Cell Designer provides both a 
graphical mechanism for constructing the pathway diagram 
shown in Fig. 1 as well as an ordinary differential equation 
(ODE) solver for calculating the various species 
concentrations values over time.  In Fig. 1, the creator of this 
pathway in Cell Designer had to “by hand” draw each and 
every species and then connect the species and instantiate the 
rate equations.  Cell Designer requires the entire pathway to be 
coded into the Cell Designer system exclusively using the Cell 
Designer program.   
Our methodology is to demonstrate that CytoSolve can 
integrate multiple biomolecular pathways without having to 
perform such “hand wiring”.  To demonstrate this, the 
following key steps are involved: 
Step 1: EGFR Model Decomposition – Decompose the 
original Kholodenko et al (1) model into four sub-models, 
which will serve as the elements which need to be integrated to 
build the whole EGFR model in Fig.1;  
Step 2: Sub-Model Solutions - Solve each of the four sub-
models using both Cell Designer and CytoSolve to test the 
accuracy and compare computation time of each approach;  
and, 
Step 3: Whole EFGR Model Solution - Enable CytoSolve to 
integrate all four sub models, each of which is distributed on 
four independent computers, with no human intervention and 
compare the integrated whole EFGR solution from CytoSolve 
with the whole EGFR solution calculated by Cell Designer. 
Cell Designer and CytoSolve’s central controller are 
executed on a Pentium 4 CPU 3.00 GHz Dell Workstation 
with 2 GB of RAM running Windows XP with Service Pack 2.  
In CytoSolve, each pathway model is treated as an independent 
entity, and is activated by communication with a central 
controller that insures mass conservation and other constraints 
on the aggregate system. Each of the individual sub-models 
(per Step 3), in the CytoSolve case, are also executed on a 
Pentium 4 CPU 3.00 GHz Dell Workstation with 2 GB of 
RAM running Windows XP with Service Pack 2. 
III. RESULTS 
There are three sets of results.  The first set of results 
represents the break-up of the EGFR pathway into its four sub-
models.  The second set of results provides the comparison of 
each sub-model executed in Cell Designer and in CytoSolve.  
The third set of results provides the entire EGFR model 
executed in both Cell Designer and CytoSolve. 
A. EGFR Model Decomposition 
The EGFR model of Kholodenko shown in Fig. 1 can also 
be considered to be derived by integrating a set of smaller 
pathways.    
There are many such smaller pathways.  In Fig. 2, Fig. 3, 
Fig. 4 and Fig. 5, diagrammatic representations of one set of 
such smaller pathways are created, and denoted as  Model 1, 
Model 2, Model 3 and Model 4, respectively, which, if 
integrated would derive the whole EGFR pathway shown 
above in Fig. 1.   
In reviewing Model 1, Model 2, Model 3 and Model 4, one 
will recognize that the species (EGF_EGFR)2-P is shared by 
all four models.  Model 3 and Model 4 share the common 
species SOS.  
 
Fig. 1.  Diagrammatic description of the whole EGFR pathway as published 
by Kholodenko et al (2).   
 





Fig.  3.  Diagrammatic description of Model 2, second portion of the whole 
EGFR model. 
  
B. Sub-Model Solutions 
Below in Table I, the results of executing each of the four 
sub-models: Model 1, Model 2, Model 3, Model 4, first in Cell 
Designer then in CytoSolve individually are presented.  
  For Cell Designer, each model was loaded in one at time 
and then executed.  For CytoSolve, CytoSolve’s central 
controller was implemented on one server and each model was 
implemented on another server.  The results in Table I for 
columns 2 and 3 are a result of averaging five different test 
runs.  The Difference is calculated as the RMS average across 
those five test runs for various species concentrations in each 
sub-model.  The difference in compute times is primarily due 
to network latency required for CytoSolve’s central controller 
to contact and receive information back from each model.  Cell 
Designer has no network latency since each model runs on the 
same server as Cell Designer. 
C. Whole EGFR Model Solution 
In this case, the full integration of all four models is 
performed to derive the whole EGFR model in Fig. 1.  For 
Cell Designer, all four models (depicted in Figs. 2-5) were 
loaded into the Cell Designer system and had to be connected 
by hand to recreate the diagram in Fig. 1.  This process took 
several hours to perform and ensure consistency and accuracy 
of the pathway as described by Kholodenko. For CytoSolve, 
the central controller was run on one machine and four 
separate computers were setup, each running one independent 
model.  Recall, the goal in this exercise was to evaluate the 
difference in solution between CytoSolve and Cell Designer as 
well as computational time differences for deriving the whole 
EGFR model. 
The results are shown in Table II. 
 
IV. CONCLUSION 
The results demonstrate the viability of CytoSolve’s unique 
distributed approach not only to solve problems that 
monolithic approaches are capable of solving but also to 
provide greater flexibility and scalability in integrating 
multiple biomolecular pathway models, which monolithic 
approaches are incapable of doing.  In CytoSolve, any one 
pathway can exist in any format on any computer, and there is 
no need to manually load, understand and interconnect each 
individual pathway, as is required in monolithic systems.  
CytoSolve generated near similar results to Cell Designer; 
more importantly, the integration of the four sub-models in 
CytoSolve did not require any manual “wiring” as is needed by 
Cell Designer.  CytoSolve’s compute time was greater than 
Cell Designer; however, most of this compute time was due to 
network latency.  Since CytoSolve works in a distributed 
parallel fashion, its compute time is a direct function of the 
compute time of the largest pathway plus the associated 
network latency.  For Cell Designer, the compute time will be 
the compute time of the whole integrated pathway.  Thus, as 
the number of pathways (sub-models) increase, Cell 
Designer’s compute time will continue to increase, while 
CytoSolve’s compute time will asymptotically reach a value 
equivalent to the compute time of the longest pathway.   
Initial results from the EGFR example has demonstrated that 
CytoSolve can serve as an alternative to the monolithic 
approaches for integrating and solving biomolecular pathways. 
Most important is CytoSolve’s core feature for integrating 
multiple pathway models, which can be distributed across 
multiple computing systems, without “hand wiring” of each 
model.  While such a manual approach may be viable for a 
 
Fig.  5.  Diagrammatic description of Model 4, fourth portion of the whole 
EGFR model. 
TABLE I 
CELL DESIGNER  AND CYTOSOLVE RESULTS 
 FOR COMPUTING EACH SUB-MODEL 
Model Cell Designer CytoSolve Difference 
Model 1 1310 ms 4271 ms 0.021% 
Model 2 1752 ms 4615 ms 0.034% 
Model 3 1763 ms 4714 ms 0.015% 
Model 4 2133 ms 5102 ms 0.017% 
 
TABLE II 
CELL DESIGNER  AND CYTOSOLVE RESULTS 
 FOR WHOLE  EGFR MODEL 
Cell 
Designer CytoSolve Difference 
3217 ms 9685 ms 0.026% 
 
 
Fig.  4.  Diagrammatic description of Model 3, third portion of the whole 
EGFR model. 
  
handful of models, it will not scale to support the integration 
of all pathway models necessary to model the whole cell.   In 
addition, there are several other reasons why the monolithic 
approach will not scale. 
First, scaling to, for example, over a hundred pathways and 
something like 10,000 equations – the level required to 
describe a single cell - would require a massive effort beyond 
the research expended to obtain the original individual 
pathways.  A monolithic approach such as Cell Designer 
would not be able to effectively scale the integration of that 
many pathways.  
Second, each pathway represents a knowledge domain, and 
it would be essentially impossible to have one person 
sufficiently knowledgeable in all the scientific areas to 
understand each of these domains well enough to manually 
construct a single monolithic program. 
Third, the monolithic approach does not provide a means 
for pathways from proprietary models to be used with other 
models that are open source.  An architecture such as 
CytoSolve’s is needed that will allow people to contribute the 
output of their pathways to an external dynamic network of 
models without revealing the details of their internal structure. 
Fourth, there has been no research to show that monolithic 
pathways can be distributed between machines for 
computational scalability.  The CytoSolve approach 
parallelizes the computations from the beginning, making 
computational parallelization automatic. 
Fifth, managing a monolithic model, composed of other sub-
models, is a change management nightmare.  Consider a small 
example of a monolithic model “cut and pasted” or 
concatenated from the four sub-models of EGFR, 
aforementioned, and each model being published and created 
by different authors.  Now, suppose once the monolithic model 
has been constructed, that many months later, the authors of 
each of these models changes rate constants, pathway 
connections, etc., at that point the author of the monolithic 
model would have to rebuild the entire monolithic model, by 
instantiating changes from each author’s model, which may be 
tenable for four sub-models (possibly based on the complexity 
and domain specificity of each model).  Modeling the whole 
cell while managing such changes across a suite of hundreds of 
such sub-models will be untenable. 
In summary, CytoSolve provides a core platform for 
addressing one of the grand challenges of Systems Biology: 
modeling the whole cell by integrating multiple biomolecular 
pathway models which span time-scales, knowledge domains 
and spatial-scales.  
V. FUTURE WORK 
Based on the results on applying CytoSolve to the EGFR 
pathway model, the following key areas of future work will be 
pursued: 
(1) Advancements to the existing controller within the 
CytoSolve architecture.  Such advancements will result from 
optimizing the time sequencing of how and when to call each 
sub-model during computation along with replacing the current 
event loop structure which has a fixed wait queue before 
processing the next computation. 
(2) Specification of ontology standards for each pathway.  
Currently, each pathway model may use the same species; 
however, they may be named differently within each pathway 
model.  There is a need to standardize the naming of species or 
provide an intermediate translation dictionary for fully 
automating the resolution of species names across pathway 
models. 
(3) Demonstration of CytoSolve using other pathway 
models.  New work is underway to use CytoSolve to solve a 
heretofore unsolved problem integrating extant pathway 
models.  Currently, the authors are exploring integrating 
multiple pathway models involved in inflammatory response 
using CytoSolve’s approach.  
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